Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ROS1 Gene Mutation”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Early research (Phase 1)Looking for participantsNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Early research (Phase 1)Study completedNCT01531361
What this trial is testing

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Who this might be right for
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant Neoplasm+2 more
M.D. Anderson Cancer Center 46
Testing effectiveness (Phase 2)Ended earlyNCT02186821
What this trial is testing

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

Who this might be right for
Tumors With Aberrations in ALK or ROS1
Novartis Pharmaceuticals 47
Testing effectiveness (Phase 2)Study completedNCT03049618
What this trial is testing

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Who this might be right for
ALK Gene MutationBRAF Gene MutationEGFR Gene Mutation+9 more
University of Southern California 42
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Testing effectiveness (Phase 2)Looking for participantsNCT04322890
What this trial is testing

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationALK Gene Mutation+2 more
Hunan Province Tumor Hospital 6,000
Testing effectiveness (Phase 2)UnknownNCT05351320
What this trial is testing

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jinming Yu 40
Testing effectiveness (Phase 2)Ended earlyNCT02846792
What this trial is testing

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Who this might be right for
ALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more
University of Washington 5
Early research (Phase 1)UnknownNCT04671849
What this trial is testing

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Who this might be right for
Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
Jiangsu Simcere Pharmaceutical Co., Ltd. 243
Not applicableLooking for participantsNCT03042221
What this trial is testing

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Who this might be right for
Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more
University of Colorado, Denver 100
Testing effectiveness (Phase 2)Study completedNCT03620643
What this trial is testing

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Who this might be right for
Lobular Breast CarcinomaGastric CancerTriple Negative Breast Cancer+1 more
Royal Marsden NHS Foundation Trust 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT03994796
What this trial is testing

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Who this might be right for
CDK Gene MutationMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm+4 more
Alliance for Clinical Trials in Oncology 50
Testing effectiveness (Phase 2)UnknownNCT03654027
What this trial is testing

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Who this might be right for
Non-small Cell Lung Cancer
First Affiliated Hospital of Guangxi Medical University 84
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Testing effectiveness (Phase 2)UnknownNCT02499614
What this trial is testing

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 80
Not applicableUnknownNCT05110950
What this trial is testing

Endobronchial Ultrasound Needle Aspiration With and Without Suction

Who this might be right for
Mediastinal LymphadenopathyHilar LymphadenopathyLymphoma+7 more
Università Politecnica delle Marche 306
Load More Results